These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29588705)

  • 21. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Baber U; Stefanini GG; Giustino G; Stone GW; Leon MB; Sartori S; Aquino M; Steg PG; Windecker S; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari DE; von Birgelen C; Dangas GD; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
    Circ Cardiovasc Interv; 2019 Jul; 12(7):e007734. PubMed ID: 31288561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
    Bavishi C; Baber U; Panwar S; Pirrotta S; Dangas GD; Moreno P; Tamis-Holland J; Kini AS; Sharma SK
    Int J Cardiol; 2017 Mar; 230():310-318. PubMed ID: 28062139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of second-generation everolimus-eluting stents compared with first-generation drug-eluting stents in diabetic patients undergoing multivessel percutaneous coronary intervention.
    Pendyala L; Loh J; Kitabata H; Minha S; Chen F; Torguson R; Suddath W; Satler L; Pichard A; Waksman R
    J Invasive Cardiol; 2015 Jun; 27(6):263-8. PubMed ID: 26028652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stent thrombosis with drug-eluting stents: is the paradigm shifting?
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Genereux P; Branzi A; Stone GW
    J Am Coll Cardiol; 2013 Nov; 62(21):1915-1921. PubMed ID: 24036025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vulnerable struts with CRE8, Biomatrix and Xience stents assessed with OCT and their correlation with clinical variables at 6-month follow-up: the CREBX-OCT study.
    Giglioli C; Formentini C; Romano SM; Cecchi E; Baldereschi GJ; Landi D; Chiostri M; Prati F; Marchionni N
    Int J Cardiovasc Imaging; 2020 Feb; 36(2):217-230. PubMed ID: 31667661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of diabetes mellitus on 2-year clinical outcomes following PCI with second-generation drug-eluting stents; Landmark analysis findings from patient registry: Pooled analysis of the Korean multicenter drug-eluting stent registry.
    Lee CH; Choi SW; Jun SW; Hwang J; Kim IC; Cho YK; Park HS; Yoon HJ; Kim H; Nam CW; Han S; Kim KB; Hur SH
    PLoS One; 2020; 15(6):e0234362. PubMed ID: 32520973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study.
    Prati F; Romagnoli E; Valgimigli M; Burzotta F; De Benedictis M; Ramondo A; Mehran R; Stella PR
    Int J Cardiol; 2014 Oct; 176(3):904-9. PubMed ID: 25171966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
    Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents.
    Kereiakes DJ; Young JJ
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S48-58. PubMed ID: 15665798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
    Kaul U; Bangalore S; Seth A; Arambam P; Abhaichand RK; Patel TM; Banker D; Abhyankar A; Mullasari AS; Shah S; Jain R; Kumar PR; Bahuleyan CG;
    N Engl J Med; 2015 Oct; 373(18):1709-19. PubMed ID: 26466202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cre8™ Unique Technology in Challenging Daily Practice: Proceedings of a satellite symposium held at EuroPCR on 20th - 23rd May 2014 in Paris.
    Mountfort K; Antoniucci D; Mehran R; DeLuca G; Nef H; Vrolix M; Khashaba A
    Interv Cardiol; 2014 Aug; 9(3):180-183. PubMed ID: 29588799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.